| Stephen R. Davis |
Stephen R. Davis is currently the Chief Executive Officer & Director at ACADIA Pharmaceuticals, Inc. He also holds the position of President, Chief Executive Officer & Director at the same company since 2015. Previously, he served as the President, CEO, CFO, COO & Secretary at Neurogen Corp. from 2008 to 2010. He was an Independent Director at Heron Therapeutics, Inc. from 2019 to 2023 and a Director at Heron Therapeutics, Inc. from 2012 to 2015. Additionally, he worked as an Executive Director at Trimeris, Inc. from 2007 to 2011. He has also served as an Independent Director at Bellicum Pharmaceuticals, Inc. from 2015 to 2024, Furiex Pharmaceuticals, Inc. from 2013 to 2014, and Synageva BioPharma Corp. from 2011 to 2015. Prior to his roles in the pharmaceutical industry, he worked as an Attorney-Corporate & Securities at Milbank LLP from 1990 to 1994. He also held the position of Chief Operating Officer & Executive Vice President at Ardea Biosciences, Inc. from 2010 to 2013. Mr. Davis completed his undergraduate degree at Southern Nazarene University in 1983 and obtained his graduate degree from Vanderbilt Law School in 1990. |
| Benir Ruano |
Benir Ruano is the founder of BDR Life Sciences LLC. He is currently working as the Senior VP-Technical Development & Operations at ACADIA Pharmaceuticals, Inc. Prior to his current position, he held the role of VP-Global Manufacturing & Technical Operations at Xeris Pharmaceuticals, Inc. and VP-Manufacturing Operations & Supply Chain at Tarsus Pharmaceuticals, Inc. Mr. Ruano has an MBA from National University and an undergraduate degree from the University of California San Diego. |
| Mark C. Schneyer |
Mark C. Schneyer is currently the Chief Financial Officer & Executive Vice President at ACADIA Pharmaceuticals, Inc. He previously worked at Pfizer Inc. as the Vice President-Business Development from 2011 to 2020. Mr. Schneyer completed his undergraduate degree at The Wharton School of the University of Pennsylvania in 1996. |
| James K. Kihara |
James K. Kihara is currently working as the Chief Accounting Officer, VP & Controller at ACADIA Pharmaceuticals, Inc. |
| Erika Parker Zavod |
Erika Parker Zavod is currently working as the SVP-Strategy, Planning, Research & Development at ACADIA Pharmaceuticals, Inc. She started this position in 2023. Prior to her current role, she has a graduate degree from Temple University (Pennsylvania) and an undergraduate degree from Clark University. |
| Brendan P. Teehan |
Brendan P. Teehan is currently the Chief Operating Officer, EVP & Head-Commercial at ACADIA Pharmaceuticals, Inc. He previously worked as the Vice President-Building & Provider Solutions at Tesaro, Inc. from 2016 to 2018, and as the Senior Vice President & Vice President at RT Oncology Services Corp. from 2012 to 2016. Mr. Teehan holds an MBA degree from Carnegie Mellon University and an undergraduate degree from the University of Notre Dame, which he received in 1990. |
| Elizabeth H. Z. Thompson |
Elizabeth H. Z. Thompson is currently the Executive VP & Head-Research & Development at ACADIA Pharmaceuticals, Inc. She previously worked as the Group Director-Scientific Clinical Development at AbbVie, Inc. from 2017 to 2018. She also held positions as a Director at IGM Biosciences, Inc. and California Life Sciences Association. Additionally, she served as the Group Vice President-Development & External Search at Horizon Therapeutics Plc from 2020 to 2021. Dr. Thompson holds a doctorate degree from The Scripps Research Institute and an undergraduate degree from Harvey Mudd College. |
| Douglas J. Williamson |
Douglas J. Williamson's current job(s) include being the Executive VP, Head-Research & Development at ACADIA Pharmaceuticals, Inc. and a Member at The Royal College of Psychiatrists. Dr. Williamson's former job(s) include being an Independent Director at Bright Minds Biosciences, Inc., the Head-Early Phase Clinical Development Neuroscience at Eli Lilly & Co., the Vice President & Global Head-Therapeutic at PAREXEL International Corp., the Senior VP, Head-US Research & Development at H. Lundbeck A, and the Chief Medical Officer at Avadel Pharmaceuticals Plc. Dr. Williamson obtained a doctorate degree from The University of Edinburgh. |
| Sanjeev Pathak |
Sanjeev Pathak is currently the Senior Vice President & Head-Clinical Development at ACADIA Pharmaceuticals, Inc. He previously worked as the Vice President-Clinical Development at Alkermes, Inc. |
| Kevin R. Oliver |
Kevin R. Oliver is currently the Chief Business Officer & Senior Vice President at ACADIA Pharmaceuticals, Inc. He also holds a current position as a Senior Vice President at Simcere Pharmaceutical Group Ltd. Previously, he worked as an Executive Director at Merck & Co., Inc. from 2010 to 2014. Dr. Oliver obtained a doctorate degree from the University of Cambridge in 1995 and an undergraduate degree from King's College London in 1990. |
| Ponni Subbiah |
Ponni Subbiah is currently the Chief Medical Officer, SVP & Head-Medical Affairs at ACADIA Pharmaceuticals, Inc. Prior to this, Dr. Subbiah worked as the Vice President-Medical Affairs & Global Access at Pfizer Inc. and as the Chief Medical Officer at Indivior PLC from 2016 to 2019. Dr. Subbiah holds a graduate degree from Johns Hopkins Bloomberg School of Public Health and undergraduate and doctorate degrees from Madras Medical College. |
| Stephen R. Biggar |
Stephen R. Biggar is currently serving as the Chairman at ACADIA Pharmaceuticals, Inc. since 2016. He is also an Independent Director at Kiniksa Pharmaceuticals Ltd. since 2015 and at TScan Therapeutics, Inc. since 2021. Additionally, he holds positions as a Director at Notch Therapeutics, Inc. and Neurogene, Inc. In his former roles, Dr. Biggar served as a Director at BioCryst Pharmaceuticals, Inc. from 2005 to 2011. He also held the position of Director at Synageva BioPharma Corp. and served as an Independent Director from 2013 to 2015. Furthermore, he was a Director at Vivelix Pharmaceuticals, Ltd. and a Partner at Baker Bros. Advisors LP. Dr. Biggar completed his undergraduate degree at Rochester Christian University. He furthered his education at Stanford University, where he obtained graduate and doctorate degrees. |
| Katherine M. Bishop |
Katherine M. Bishop is currently the Director at DTx Pharma, Inc. since 2022 and the SVP, Head-Rare Disease & External Innovation at ACADIA Pharmaceuticals, Inc. since 2021. Previously, she worked as the Director-Preclinical Research & Development at Ceregene, Inc. from 2001 to 2009, Vice President-Clinical Development at Ionis Pharmaceuticals, Inc. from 2009 to 2015, Chief Scientific Officer at Tioga Pharmaceuticals, Inc. in 2015, Chief Scientific Officer at Otonomy, Inc. from 2017 to 2019, and Chief Scientific Officer at Locanabio, Inc. from 2019 to 2020. Dr. Bishop holds a doctorate degree from the University of Alberta, and undergraduate degrees from the University of British Columbia and Simon Fraser University. |
| Bob Mischler |
Bob Mischler is currently working as the Senior VP-New Product Planning & Strategy at ACADIA Pharmaceuticals, Inc. Prior to his current position, he worked as the Vice President-Commercial Planning & Analytics at Ardea Biosciences, Inc. Mr. Mischler completed his undergraduate degree at Indiana University in 1987 and later obtained an MBA from UCLA Anderson School of Management in 1993. |
| Rob Ackles |
Rob Ackles is currently the Chief People Officer & Senior Vice President at ACADIA Pharmaceuticals, Inc. He completed his undergraduate degree at the University of California, Santa Barbara. |
| Edmund P. Harrigan |
Edmund P. Harrigan is an Independent Director at Incyte Corp., ACADIA Pharmaceuticals, Inc., PhaseBio Pharmaceuticals, Inc., and AlgoTherapeutix SAS. He previously served as an Independent Director at Bellicum Pharmaceuticals, Inc. from 2018 to 2019, an Independent Non-Executive Director at Karuna Therapeutics, Inc. from 2011 to 2020, and as a Senior VP-Worldwide Safety & Regulatory at Pfizer Inc. from 2012 to 2015. Harrigan's education includes an undergraduate degree from St. Anselm College in 1974 and a doctorate degree from UMass Chan Medical School in 1979. |
| Daniel B. Soland |
Daniel B. Soland is an Independent Director at ACADIA Pharmaceuticals, Inc. and DBV Technologies SA. He previously served as the President & Chief Executive Officer at Epigenesis Pharmaceuticals LLC from 2002 to 2005. He was also the Chief Executive Officer & Executive Director at uniQure NV in 2016. Prior to that, he held the position of Director-Worldwide Marketing Operations & VP at Corixa Corp. and GSK Plc from 1993 to 2002. He served as a Non-Executive Director at Oxford Biomedica Plc from 2015 to 2016. Additionally, he has been an Independent Director at KalVista Pharmaceuticals, Inc. since 2019. Mr. Soland has a background in undergraduate studies from the University of Iowa. |
| Laura A. Brege |
Laura A. Brege currently works at Council on International Educational Exchange, Inc., as Chairman, ACADIA Pharmaceuticals, Inc., as Independent Director from 2008, Pacira Biosciences, Inc., as Independent Director from 2011, Pacira Pharmaceuticals, Inc. (California), as Director from 2011, Ohio University Foundation, as Director, HLS Therapeutics, Inc., as Independent Director from 2019, Edgewise Therapeutics, Inc., as Independent Non-Executive Director from 2020, Mirum Pharmaceuticals, Inc., as Independent Director from 2019, and T-Knife Therapeutics, Inc., as Director from 2021. Ms. Brege also formerly worked at Nodality, Inc., as President, Chief Executive Officer & Director from 2013 to 2015, Delcath Systems, Inc., as Independent Director from 2013 to 2014, Dynavax Technologies Corp., as Independent Director from 2015 to 2020, Angiotech Pharmaceuticals, Inc., as Director from 2007 to 2011, Portola Pharmaceuticals LLC, as Independent Director from 2015 to 2020, Zvents, Inc., as Director, Aratana Therapeutics, Inc., as Independent Director from 2014 to 2019, Avexus, Inc., as Director, The Bay Area Bioscience Association, as Independent Director, Cervantes Life Science Partners LLC, as Managing Director from 2015 to 2018, California Life Sciences Association, as Director, The Cooper Cos., Inc., as Treasurer & Vice President from 1982 to 1988, COR Therapeutics, Inc., as Chief Financial Officer & Senior Vice President from 1991 to 1999, Onyx Pharmaceuticals, Inc., as Chief Operating & Business Officer, Executive VP from 2006 to 2011, Flextronics Corp., as Chief Financial Officer & Vice President from 1988 to 1991, and Red Rock Capital Management, Inc., as General Partner from 1999 to 2008. Ms. Brege received her Masters Business Admin degree in 1982 from The University of Chicago, undergraduate degree in 1978 from The Ohio University, and Masters Business Admin degree from The University of Chicago Booth School of Business. |
| Julian Charles Baker |
Julian Charles Baker is the founder and the Managing Partner of Baker Bros. Advisors LP, which was founded in 2000. He is currently the Independent Chairman at Madrigal Pharmaceuticals, Inc. since 2023, Lead Independent Director at Incyte Corp. since 2001, Independent Director at ACADIA Pharmaceuticals, Inc. since 2015, Independent Director at Prelude Therapeutics, Inc. since 2021, Director at EveryONE Medicines, Inc., Director at Alumis, Inc., Managing Member at Baker Bros. Advisors GP LLC, and Partner at FBB Associates. Mr. Baker has held former positions as Director at Neurogen Corp. from 1999 to 2009, Independent Director at Idera Pharmaceuticals, Inc. from 2014 to 2018, Director at Trimeris, Inc. from 2004 to 2011, Lead Independent Director at Genomic Health, Inc. from 2001 to 2019, Director at Innoviva, Inc. from 1999 to 2007, Director at Presidio Pharmaceuticals, Inc., Member at Credit Suisse First Boston Corp. from 1988 to 1993, Principal at CSFB Private Equity Partners LLC, Advisory Board Member at Elm Street Advisors LLC, and Portfolio Manager at Tisch Financial Management from 1994 to 1999. Mr. Baker obtained his undergraduate degree from Harvard University. |
| James M. Daly |
James M. Daly is currently serving as an Independent Director at ACADIA Pharmaceuticals, Inc., argenx SE, and Madrigal Pharmaceuticals, Inc. He previously held positions as an Independent Director at Halozyme Therapeutics, Inc., Chimerix, Inc., and Bellicum Pharmaceuticals, Inc. He also served as the SVP-Global Marketing & Commercial Development at Amgen, Inc. from 2002 to 2011 and as the Chief Commercial Officer & Executive VP at Incyte Corp. from 2012 to 2015. Additionally, he has held positions at Coherus BioSciences, Inc., Amgen Ventures LLC, and Francis Cauffman, Inc. Mr. Daly obtained his undergraduate degree in 1983 and an MBA in 1985 from the State University of New York at Buffalo. |
| Elizabeth A Garofalo |
Elizabeth A Garofalo currently works at ACADIA Pharmaceuticals, Inc., as Independent Director from 2020, Xenon Pharmaceuticals, Inc., as Independent Director from 2021, Alector, Inc., as Independent Director from 2021, Institute For Advanced Clinical Trials For Children, as Director, and EAG Pharma Consulting LLC, as Principal from 2016. Dr. Garofalo also formerly worked at Exicure, Inc., as Chairman from 2022 to 2023, Pfizer Inc., as Head-Neuroscience & Worldwide Regulatory Affairs, Novartis International AG, as Global Head-Clinical Development & Senior VP, and Astellas Pharma Global Development, Inc., as VP & Head-Neuroscience Therapy Area. Dr. Garofalo received her undergraduate degree from Purdue University and doctorate degree from The Indiana University School of Medicine. |
